Savolitinib Plus Osimertinib Show a High Response in EGFR-mutated NSCLC Progressed on First-Line Osimertinib Due to MET-driven Resistance Mechanisms By Ogkologos - August 6, 2025 618 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the SAVANNAH study Source RELATED ARTICLESMORE FROM AUTHOR Giredestrant plus everolimus prolongs PFS among patients with ER-positive, HER2-negative, ESR1-mutated advanced breast cancer after the receipt of a CDK4/6 inhibitor EMA Recommends Granting a Marketing Authorisation for Ensartinib Taking on the RAS Challenge MOST POPULAR EMA Recommends Granting a Conditional Marketing Authorisation for Adagrasib Following a Re-Examination... November 17, 2023 T-DM1 Approval Expanded to Include Some Women with Early-Stage HER2-Positive Breast... May 23, 2019 Teacher Reads To Students One Day After Having Brain Surgery October 26, 2021 Breast Cancer Patient Does Head-Shaving Photo Shoot in Hopes of Inspiring... March 24, 2021 Load more HOT NEWS The R50 Research Specialist Award: Ensuring a Stable Cancer Research Workforce Looking back at a life-changing clinical trial Advanced MRI could help to differentiate aggressive and slower growing prostate... Clinical Utility of ctDNA NGS for Detecting Actionable Alterations According ESCAT...
